JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.

Cancer Res

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Published: February 2016

Entire or partial deletions of the male-specific Y chromosome are associated with tumorigenesis, but whether any male-specific genes located on this chromosome play a tumor-suppressive role is unknown. Here, we report that the histone H3 lysine 4 (H3K4) demethylase JARID1D (also called KDM5D and SMCY), a male-specific protein, represses gene expression programs associated with cell invasiveness and suppresses the invasion of prostate cancer cells in vitro and in vivo. We found that JARID1D specifically repressed the invasion-associated genes MMP1, MMP2, MMP3, MMP7, and Slug by demethylating trimethyl H3K4, a gene-activating mark, at their promoters. Our additional results demonstrated that JARID1D levels were highly downregulated in metastatic prostate tumors compared with normal prostate tissues and primary prostate tumors. Furthermore, the JARID1D gene was frequently deleted in metastatic prostate tumors, and low JARID1D levels were associated with poor prognosis in prostate cancer patients. Taken together, these findings provide the first evidence that an epigenetic modifier expressed on the Y chromosome functions as an anti-invasion factor to suppress the progression of prostate cancer. Our results also highlight a preclinical rationale for using JARID1D as a prognostic marker in advanced prostate cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755879PMC
http://dx.doi.org/10.1158/0008-5472.CAN-15-0906DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
prostate tumors
12
prostate
9
prognostic marker
8
jarid1d levels
8
metastatic prostate
8
jarid1d
7
cancer
5
jarid1d suppressor
4
suppressor prognostic
4

Similar Publications

Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.

Int Urol Nephrol

January 2025

Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany.

Purpose: To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Methods: Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression.

View Article and Find Full Text PDF

Purpose: The study explores the role of multimodal imaging techniques, such as [F]F-PSMA-1007 PET/CT and multiparametric MRI (mpMRI), in predicting the ISUP (International Society of Urological Pathology) grading of prostate cancer. The goal is to enhance diagnostic accuracy and improve clinical decision-making by integrating these advanced imaging modalities with clinical variables. In particular, the study investigates the application of few-shot learning to address the challenge of limited data in prostate cancer imaging, which is often a common issue in medical research.

View Article and Find Full Text PDF

Background: Active surveillance (AS) is the guideline-recommended treatment for low-risk prostate cancer and involves routine provider visits, lab tests, imaging, and prostate biopsies. Despite good uptake, adherence to AS, in terms of receiving recommended follow-up testing and remaining on AS in the absence of evidence of cancer progression, remains challenging.

Objective: We sought to better understand urologist, primary care providers (PCPs), and patient experiences with AS care delivery to identify opportunities to improve adherence.

View Article and Find Full Text PDF

Objectives: To develop and validate a lesion-based grading system using clinicopathological and MRI features for predicting positive surgical margin (PSM) following robotic-assisted laparoscopic prostatectomy (RALP) among prostate cancer (PCa) patients.

Methods: Consecutive MRI examinations of patients undergoing RALP for PCa were retrospectively collected from two medical institutions. Patients from center 1 undergoing RALP between January 2020 and December 2021 were included in the derivation cohort and those between January 2022 and December 2022 were allocated to the validation cohort.

View Article and Find Full Text PDF

Squared diffusion-weighted imaging for improving the detection of clinically significant prostate cancer.

Sci Rep

January 2025

Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany.

Aim of this study was to proof the concept of optimizing the contrast between prostate cancer (PC) and healthy tissue by DWI post-processing using a quadrature method. DWI post-processing was performed on 30 patients (median age 67 years, prostate specific antigen 8.0 ng/ml) with PC and clear MRI findings (PI-RADS 4 and 5).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!